AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Especially, the interplay of MYC and hsa-miR-144 has been reported in chronic myelogenous leukemia cell K562 [75], and the transcription factor E2F1 could also up-regulate miR-224/452 expressions to inhibit the expression of TXNIP to drive EMT in malignant melanoma [36], as well as miR-3188, as a tumour suppressor, could control the nasopharyngeal carcinoma proliferation and chemosensitivity through a mechanism where FOXO1 modulated a positive feedback loop of mTOR-p-PI3K/AKT-c-JUN [38].